What Does the "-glutide" Suffix Mean? GLP-1 Drug Names Decoded

What Does the "-glutide" Suffix Mean? GLP-1 Drug Names Decoded

Every GLP-1 drug name hides a code.

Key Takeaways

• -glutide means GLP-1: Any drug ending in "-glutide" is a GLP-1 receptor agonist peptide.
• -patide means dual receptor: The "-patide" stem signals a drug targeting more than one incretin receptor — like GLP-1 and GIP together.
• -tide means peptide: Both stems share the "-tide" root, indicating the drug is a chain of amino acids.
• Non-peptides break the pattern: Orforglipron activates the GLP-1 receptor but has no "-glutide" suffix because it is a small molecule, not a peptide.
• Exenatide is the outlier: It ends in "-natide," not "-glutide," because it derives from a lizard peptide rather than human GLP-1.

Once you understand the naming code, you can pick up any GLP-1 drug name — including ones approved after this article was written — and know exactly what kind of molecule you are dealing with, how it works, and what receptor targets it hits. That knowledge takes about five minutes to acquire and is useful for the rest of your life.

Why drug names have structure at all

Branding is chaos — names like Ozempic, Victoza, and Zepbound tell you nothing. The WHO's International Nonproprietary Name (INN) system exists to solve that. Every prescription drug gets a globally recognized nonproprietary name built from standardized building blocks called stems. Stems are assigned by pharmacological category, so chemists, pharmacists, and clinicians in any country can decode what a drug does just from reading its name. The system has been running since 1953. GLP-1 receptor agonists got their stems when the first ones entered clinical development, and every drug approved since then has followed the same rules.

Think of it like a word you can always look up the root of. Once you know that "-cillin" means beta-lactam antibiotic and "-statin" means HMG-CoA reductase inhibitor, you never forget it. GLP-1 drugs have two key stems: "-glutide" and "-patide." Learning both takes two minutes.

What "-glutide" actually means

"-Glutide" is broken down as follows: "-gl-" traces to glucagon-like peptide, "-u-" is a connector, "-tide" signals a peptide drug. Together the stem says: this is a peptide-based drug in the GLP-1 receptor agonist class. Every drug bearing it was modeled on human GLP-1 (the naturally occurring hormone), engineered to resist the enzyme DPP-4 that breaks natural GLP-1 down within about two minutes.

The drugs carrying this stem include:

• Semaglutide — sema + glutide. The prefix "sema" has no special pharmacological meaning; it's a proprietary identifier. The "-glutide" does all the classification work.

• Liraglutide — lira + glutide. Same logic. "Lira" is proprietary shorthand.

• Dulaglutide — dula + glutide. The "dula" prefix refers to the dual-chain structure of the molecule (it's fused to an antibody fragment), not to dual receptor targets.

• Albiglutide — albi + glutide. "Albi" references albumin fusion technology used to extend half-life. (Withdrawn from market in 2018 for business reasons, not safety.)

If a drug ends in "-glutide," you now know: peptide drug, GLP-1 receptor agonist, modeled on human GLP-1. That's the whole message.

Why tirzepatide gets a different stem: "-patide"

Tirzepatide targets two receptors at once — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). That's a meaningfully different mechanism, not just an upgrade of the same drug. The WHO reflected that mechanistic distinction in the name: "-patide" was assigned as the stem for dual or multi-incretin receptor agonist peptides.

Break it down: "-p-" suggests the poly-agonist character (targeting multiple receptors), "-a-" is a connector, "-tide" again signals peptide. The stem tells you, before you read a single clinical trial, that this drug is doing something GLP-1 agonists alone are not: activating the GIP receptor pathway simultaneously. That dual activation is why tirzepatide (Mounjaro/Zepbound) produced 22.5% average body weight loss at 72 weeks in the SURMOUNT-1 trial — a result that noticeably outpaces single-agonist "-glutide" drugs.

Retatrutide, currently in Phase 3 trials, is a triple agonist (GLP-1 + GIP + glucagon receptor). Its INN ends in "-patide" as well, consistent with the multi-receptor-agonist category.

The exenatide outlier: "-natide"

Exenatide (Byetta, Bydureon) does not end in "-glutide." It ends in "-natide," which signals a different origin story entirely. The molecule was derived from exendin-4, a peptide found in the saliva of the Gila monster lizard. Exendin-4 happens to activate the GLP-1 receptor in humans, but it is not structurally a GLP-1 analogue — it is a homologue from a different species. It is naturally resistant to DPP-4 degradation, which is one reason it became interesting pharmaceutically. The "-natide" stem was assigned to reflect this non-human-GLP-1 origin while still indicating peptide-based incretin agonism.

Lixisenatide, another exendin-based drug, carries the same "-natide" stem for the same reason.

When the naming system breaks: orforglipron

Here is where it gets interesting. Orforglipron (Foundayo, Eli Lilly) activates the GLP-1 receptor — same target as semaglutide, same downstream effects — but it contains no "-glutide" or "-tide" in its name at all. That is not an accident. Orforglipron is a small molecule, not a peptide. It works by fitting into the receptor through a completely different structural route. Because it is not a peptide, it does not get a "-tide" suffix of any kind. The INN stem for non-peptide GLP-1 receptor agonists is "-glipron," which you can see embedded in "orfor-GLIPRON."

"-Glipron" is the emerging stem for orally available, non-peptide GLP-1 receptor agonists. Danuglipron (Pfizer) carries the same stem. This matters practically: small-molecule "-glipron" drugs can be taken as standard once-daily pills without fasting requirements or special delivery technology — a meaningful difference from the peptide-based Wegovy pill, which requires 30 minutes fasting and a very small amount of water before eating.

The "-tide" root unifying almost everything

Step back and notice that "-glutide," "-patide," and "-natide" all end in "-tide." That shared root is not coincidental. In INN nomenclature, "-tide" consistently marks peptide drugs — molecules built from chains of amino acids. The subclass stems tacked onto it (the "-glu-," "-pa-," "-na-" portions) tell you which receptor family and structural origin. Peptide GLP-1 drugs will almost always carry some form of "-tide" in their INN. When that disappears — as with orforglipron — you are looking at a structurally different category of drug even if the receptor target is the same.

Full quick-reference decoding table

Reading a brand-new drug name you've never seen

Here is the practical payoff. Suppose a new drug called "fetaglutide" is announced tomorrow. You have never heard of it. But now you know: "-glutide" means GLP-1 receptor agonist, peptide-based, modeled on human GLP-1. You know its class, its general mechanism, its peptide nature, and roughly what side effect profile to expect — all before reading a single sentence about it. If it were called "netatrutide," the "-patide" hidden in the "-trutide" phonetics would tip you off to multi-receptor agonism. If it ended in "-glipron," you would know it was an oral small molecule.

The INN naming system means the molecule's class is always visible in its generic name — if you know what to look for. "-glutide" = GLP-1 peptide. "-patide" = multi-incretin peptide. "-glipron" = non-peptide GLP-1 small molecule. Those three stems cover almost every GLP-1 class drug currently approved or in late-stage development.

One real limitation of the naming system

The INN stems tell you the mechanism category, not the clinical outcome. Two drugs with "-glutide" stems — say, liraglutide and semaglutide — can produce 8% versus 15% weight loss respectively despite sharing the same stem. The stem is structural shorthand, not a performance indicator. Knowing tirzepatide's "-patide" stem tells you it is a dual agonist, but it does not tell you that it outperforms semaglutide 2.4 mg by approximately 7–8 percentage points on weight loss. For that, you still need the trial data.

Frequently Asked Questions

Does every GLP-1 drug end in "-glutide"?
No. Exendin-based drugs end in "-natide." Dual or multi-receptor agonist peptides end in "-patide." Non-peptide small molecule agonists end in "-glipron." The "-glutide" stem specifically means peptide-based, human-GLP-1-modeled, single GLP-1 receptor agonist.

Why does tirzepatide have "-patide" instead of "-glutide"?
Because it activates both the GLP-1 receptor and the GIP receptor simultaneously. The WHO assigned the "-patide" stem to mark that mechanistic distinction — activating two different incretin receptors, not one.

What does "-tide" by itself signal?
In INN nomenclature, "-tide" marks a peptide drug — a molecule built from a chain of amino acids. Most GLP-1 drugs carry this root in one form or another. When it's absent (as in orforglipron), the drug is a small molecule, not a peptide.

What stem would a completely new triple-agonist drug get?
Almost certainly "-patide," the stem now used for multi-receptor incretin peptide agonists. Retatrutide, a GLP-1/GIP/glucagon triple agonist currently in Phase 3, carries the "-patide" stem on that basis.

Where does the WHO INN system publish official stem definitions?
The WHO publishes its complete list of INN stems on its official website. The document is titled "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" and is freely available.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication.